MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway

Mesenchymal stem cells (MSCs) are favourable treatments for ischaemic diseases; however, MSCs from diabetic patients are not useful for this purpose. Recent studies have shown that the expression of miR-34a is...

Source: Stem Cell Research and Therapy - February 5, 2021 Category: Stem Cells Authors: Fengyun Zhang, Fei Gao, Kun Wang, Xiaohong Liu and Zhuoqi Zhang Tags: Research Source Type: research